Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.
2022, COCHRANE LIBRARY, Pages 1-13 (volume: 2022)
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation (01a Articolo in rivista)
Occhipinti M., Ferrara R., Imbimbo M., Simeon V., Fiscon G., Marchal C., Skoetz N., Viscardi G.
Gruppo di ricerca: Bioengineering and Bioinformatics